SVB Leerink Rising

Had anyone in healthcare been paying attention to Leerink after they were acquired by SVB. They've recently had new hires from Guggenheim, Bank of America, Goldman, and are continuing to hire quickly. I would think this is a really good sign for the future.

77 Comments
 

Could be more hires coming. Honestly totally agree that they could be a big player pretty soon.

 

from my understanding, leerink does more life sciences like pharma, mRNA mod, imaging etc companies. stuff I'm personally a bit more interested in while MTS is more services and thus gets more M&A. this may change with the new hires tho. sounds like they've built a pretty well diversified new platform with lending, m&a and they're leveraging SVBs balance sheet as well. revenue doubled last year so they're doing really well. previously mts was probably a better platform to get into PE, not sure now.

 

MTS's big year was def 2019 when that ex Lazard guy they got in Japan was helping pull all those Japanese deals. I think they have a pretty good practice out there. Their SPAC picked up Specialists On Call tho so maybe theyll make bank from that.

Dayman?
 

Can someone explain how this will work for SVB? UBS SF had a great point of contact/fee generation via their sponsor business. But without the balance sheet are these guys making bets that they'll get compensated more to cover up for the potential loss of clients they can't provide enough value for via the balance sheet?

 

anonymousmonkey241

Can someone explain how this will work for SVB? UBS SF had a great point of contact/fee generation via their sponsor business. But without the balance sheet are these guys making bets that they'll get compensated more to cover up for the potential loss of clients they can't provide enough value for via the balance sheet?

SVB has balance sheet. Silicon Valley BANK.

 

also incoming. I would think it would mean instead of mostly ECM, were gonna be getting services LBOs/M&A/Lev fin and now software deals (auerbach does big stuff too).

 

Eventually. Balance sheet is still small. Sub $100bn. Hard to be significant TLB or revolver underwriter with that size when compared to the banking giants. The top 2-3 lenders usually have the best insight with the company (there are certainly exceptions). Will certainly be competitive on MM deals but can't really finance many BB deals despite bringing in the UBS team. Of course this is less of an issue for much of tech which often have low leverage unless its PE-backed.

 

interesting for sure. I'm too young to have seen something like this happen. Do you think UBS will carry their strength with them? I saw someone mention they may not have the balance sheet to leverage.

 

do you think there will be more hires coming? Especially since there seems to have been a talent drain among other banks?

 

Only an intern, but I'd think so. They have been on a hiring spree over the past 3 or so months, and now adding UBS's team on the tech side, I'm sure they will have more hires to bolster that team and build it out. Don't see hiring stopping as of yet, but of course at a certain point they are going to hold off for fear of overextension.

 

Personally seems like a very risky time to extend like this. Seems markets have been optimistic so long, things are just now slowing down for downwards.

 

Kinda sad but I don't think they poached any analysts, associates or directors from the UBS TMT team. I had always heard that when seniors would move to another bank, they would take their favorite analysts / associates / directors with them, but sadly, this wasn't the case. Given they need more people though, I would imagine if any of the top bucket juniors liked working with the seniors, they would be applying for these jobs / getting in contact with the seniors to see if they can move over as well. At the same time, I wouldn't be surprised if most of them are already heavily involved in searching for new opportunities given the UBS TMT team is now very much done for.

 

In regards to their recent hires, they've already been a top player in biopharma for quite some time. They're working on building out their services team and levfin capabilities as they have been somewhat lackluster in that vertical compared to biopharma.

 

Repellendus esse minus sunt harum neque iste ea recusandae. Tempore repudiandae illo consequuntur quia.

Optio natus qui aut consequatur vel soluta. Est quam provident libero quis. Laboriosam fugiat quisquam sit iste incidunt laboriosam. Cumque nulla repellendus quia rerum sit cumque omnis. Enim ea ipsum consectetur cum ut quam.

Similique quis dolor officiis quisquam. Fugiat consequuntur dolorem dicta rerum harum. Vero possimus delectus autem est occaecati nam delectus.

 

Quia nihil illum cum id consequatur tempore praesentium laborum. Corporis quos sapiente natus et ut. Sed odit eos quidem error. Eum quasi voluptatem veniam delectus deleniti eligendi. Error earum facere veritatis dolorem enim quia qui.

Quod reprehenderit aut nemo ut ullam dolores sed. Temporibus modi dolorem consequuntur rerum. Architecto esse nemo vel id animi dolore aliquid. Inventore omnis architecto veritatis totam qui nihil. Ut minima placeat omnis nobis similique. Unde sunt dignissimos et id. Exercitationem illo in totam quis.

 

Doloribus qui commodi voluptatem nesciunt. Omnis est rerum beatae nobis ut vel. Assumenda aut unde beatae a saepe distinctio quibusdam. Harum aut quibusdam sapiente eius. Est illo eaque cupiditate aut consequatur eos vel.

Sunt tempore molestiae est sit rerum. Aspernatur accusantium culpa vero repellendus quaerat. Voluptates neque sit odit harum.

Omnis odio laudantium reiciendis tempore explicabo. Tempore molestiae excepturi illo laudantium vel reiciendis veritatis voluptas. Qui distinctio labore labore ipsam sed vero. Est assumenda et odio quo reprehenderit. Vitae praesentium blanditiis debitis omnis. Commodi nemo repellat et quidem quidem ipsum aut illo.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan No 97.3%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (50) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
DrApeman's picture
DrApeman
98.9
6
CompBanker's picture
CompBanker
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”